Edition:
United States

People: MannKind Corp (MNKD.O)

MNKD.O on Consolidated Issue listed on NASDAQ Global Market

0.61USD
30 Sep 2016
Change (% chg)

$0.02 (+2.69%)
Prev Close
$0.60
Open
$0.58
Day's High
$0.63
Day's Low
$0.57
Volume
1,899,505
Avg. Vol
3,747,266
52-wk High
$3.79
52-wk Low
$0.55

Nordhoff, Henry 

Mr. Henry L. Nordhoff is an Independent Director of MannKind Corporation., since March 18, 2005. He has served as a director of BioTime, Inc. since June 2013 and as a director of Asterias Biotherapeutics, Inc. since October 2013. Mr. Nordhoff retired as Chairman of the Board of Gen-Probe Incorporated, a clinical diagnostic and blood screening company, at the end of 2011, after serving as its Chairman since September 2002. He also served as Chief Executive Officer and President of Gen-Probe from July 1994 until May 2009. Prior to joining Gen-Probe, he was President and Chief Executive Officer of TargeTech, Inc., a gene therapy company that was merged into Immune Response Corporation. Prior to that, Mr. Nordhoff was at Pfizer, Inc. in senior positions in Brussels, Seoul, Tokyo and New York. He received a B.A. in international relations and political economy from Johns Hopkins University and an M.B.A. from Columbia University. The Board believes that Mr. Nordhoff’s business experience, including his experience as a director and executive officer at pharmaceutical and biotech companies, combined with his business acumen and judgment provide our Board with valuable operational expertise and leadership skills.

Basic Compensation

Total Annual Compensation, --
Restricted Stock Awards, --
Long-Term Incentive Plans, --
All Other, --
Fiscal Year Total, --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --